A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma

Stopped early · Phase 1

Conditions studied: Relapsed Ewing Sarcoma

In brief

The purpose of this study is to evaluate the safety and preliminary antitumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy.

Key facts

Study ID
NCT03514407
Run by
Incyte Corporation
People needed
25
Starts
2018-06-27
Expected to finish
2020-06-25
Last updated by the study team
2025-10-21

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.